Novartis AC to acquire European Commission Approval for Tabrecta, lapatinib, to cure small cell lung cancer. Tabrecta also provides specialized therapy for cured patients living with NSCLC.
Hikma Pharmaceuticals PLC to announce to completion of the acquisition of Custopharm Inc. The company is acquired from Water Street Healthcare Partners by getting approval from the US Federal Trade Commission.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 4174
Published Date: Jul 27, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Rising incidences of bacterial infections across the globe and the significant increment in global geriatric population are the major factors driving the growth of the market.
The market size of Optic Neuritis Treatment is anticipated to attain a CAGR of 5% over the forecast period, i.e., 2023 Ã¢â‚¬â€œ 2035.
The major players in the market are Santen Pharmaceuticals Co., Ltd., Mallinckrodt plc, AbbVie Inc., Novartis AG, Sanofi-aventis Groupe, AdvoCare International, and others.
The hospital sub-segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.